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Available online 2 July 2015The live-attenuated Yellow Fever (YF) vaccine YF-17D induces a broad and polyfunctional CD8 T cell response in
humans. Recently, we identiﬁed a population of stem cell-like memory CD8 T cells induced by YF-17D that per-
sists at stable frequency for at least 25 years after vaccination. The YF-17D is thus amodel systemof human CD8T
cell biology that furthermore allows to track and study long-lasting and antigen-speciﬁc human memory CD8 T
cells. Here, we describe in detail the sample characteristics and preparation of a microarray dataset acquired for
genome-wide gene expression proﬁling of long-lasting YF-speciﬁc stem cell-like memory CD8 T cells, compared
to the reference CD8 T cell differentiation subsets from total CD8 T cells. We also describe the quality controls,
annotations and exploratory analyses of the dataset. The microarray data is available from the Gene Expression
Omnibus (GEO) public repository with accession number GSE65804.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).(SpeciﬁcationsCrganism/cell line/tissue Homo sapiens
x Male or female (Table 1)
rray type Agilent Whole Human Genome Microarray 8x60K
(v2; one color, Cy3) – Agilent Technologies
ata format Raw and processed (normalized expression levels)
xperimental factors RNA samples originate from CD8 T cell populations
(Table 2) isolated from cryopreserved peripheral
blood mononuclear cells (PBMC). RNA was extracted
and ampliﬁed by Miltenyi Biotec SuperAmpTM
technology.xperimental features CD8 T cell populations were puriﬁed by ﬂow cytom-
etry from 8 different healthy donors vaccinated with
Yellow Fever 17D (donors d1 to d8, Table 1); the
populations (“cell types”, Table 2) include: A2/NS4b
tetramer positive CCR7+ CD45RA+ CD8 T cells
(“A2_NS4b Naïve-like”), “Total Naïve” (CCR7+
CD45RA+), “Total Tscm” (Stem-cell like memory T:
CCR7+ CD45RA+ CD58+ CD95+), “Total CM”
(Central Memory: CCR7+ CD45RA-) and “Total Ef-
fector” (CCR7-).mmunotherapy Group, Ludwig
n des Boveresses 155, CH-1066
d and SIB Swiss Institute of
. This is an open access article under thcontinued)
SpeciﬁcationseonsentCC BY-NC-ND license (http:Samples were obtained from participants under
written informed consent following study protocol
approval by the Human Research Ethics Committee
of the Canton de Vaud (Switzerland).mple source location Lausanne, SwitzerlandSa1. Direct link to deposited data
http://www.dtd.nlm.nih.gov/geo/query/acc.cgi?acc=GSE65804
2. Experimental design, materials and methods
2.1. Experimental design
The microarray experiment detailed here was performed in the
framework of our recent study on the characterization of CD8+ stem
cell-like memory T (CD8 Tscm) cells identiﬁed in Yellow Fever YF-17D
vaccinees that persist for decades following vaccination [1]. The design
of the microarray analysis was aimed to characterize the genome-
wide RNA expression proﬁles of this population of long-lasting YF-
speciﬁc CD8 Tscm. The cells of interest were isolated from 8 different
vaccinees, spanning up to 17 years of vaccination history, male or
female, as detailed in Table 1. YF-speciﬁc CD8 Tscm were analyzed
and isolated from peripheral blood of the eight vaccinees based on the//creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Donors (YF-17D vaccinees) from whom the 5 different T cell populations were isolated.
Donor Gender Age Years since YF-17D vaccination Isolation (sort) day
d1 Female 25.4 2.4 I
d2 Female 25.9 4.1 II
d3 Female 26.8 7.2 I
d4 Male 33.6 7.9 I
d5 Female 30.7 8.7 II
d6 Female 23.6 12.1 I
d7 Male 41.4 12.7 II
d8 Male 26.6 17.8 II
Table 2
T cell populations (“cell types”) isolated from each donor for microarray analysis. All pop-
ulations were sorted from CD8 T-enriched samples by gating within live (Vivid aqua-)
CD8+ CD16- cells after doublet exclusion.
Sample title in GEO
database
T cell population Markers used for
ﬂow cytometry
sorting
A2_NS4b_ naivelike YF-17D-speciﬁc CD8 T cells, naïve-like
(Tscm)
A2/NS4b+
CCR7+ CD45RA+
total_naive Naïve in total CD8 T CCR7+ CD45RA+
total_Tscm Tscm in total CD8 T CCR7+ CD45RA+
CD95+ CD58+
total_cm CM in total CD8 T CCR7+ CD45RA-
total_effector Effectors (EM + EMRA) in total CD8 T CCR7-
298 S.A. Fuertes Marraco et al. / Genomics Data 5 (2015) 297–301detection of T cells bearing a TCR speciﬁc for the HLA-A*02-restricted
epitopeNS4b214–222 (LLWNGPMAV) of YF-17D [1,2], within the conven-
tional Naïve gate: for the microarray, they are referred to as “A2/NS4b
Naïve-like”. As reference populations, various differentiation subsets
were also isolated from the total pool of circulating CD8 T cells, includ-
ing: total Naïve, total CM, and total effectors (CCR7- cells, i.e. a mixture
of effector memory (EM) and effector memory CD45RA+ (EMRA)).We
also isolated the more recently described total population of CD8 Tscm
[3,4]. The nomenclature and markers used to isolate these ﬁve popula-
tions are listed in Table 2.25
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Fig. 1. Signal intensity distribution (raw and processed data). A. Signal intensity distribution of
tribution after the processing steps described in the text (background subtraction, quantile norm
sample. The samples are colored by the “cell type” annotation.2.2. Sample collection, preparation & cryopreservation
Healthy volunteers vaccinated with YF-17D donated circulating
leukocytes according to the standards of the Blood Transfusion Center
in Epalinges, Switzerland (Service Vaudois de Transfusion Sanguine).
Donations were performed either via leukapheresis (all donors except
d2) or a standard complete blood donation where the leukocyte-rich
fraction (buffy coat) was recovered for the study (d2 only). Peripheral
blood mononuclear cells (PBMC) were separated by density gradient
fractionation using Lymphoprep™. All samples were immediately cryo-
preserved in RPMI 1640 supplemented with 40% FCS and 10% DMSO.
2.3. Isolation of CD8 T cell populations
Freshly thawed PBMC were ﬁrst enriched for CD8 T cells using the
human CD8 T cell enrichment kit from StemCell™ Technologies (nega-
tive selection, per manufacturer's instructions). For ﬂow cytometry-
based isolation of CD8 T cell populations, stainings were performed
using PBS with 5 mM EDTA, 0.2% BSA and 0.2% Na-azide (FACS buff-
er) and all steps were carried out at 4 °C. Enriched CD8 T cells were
ﬁrst stained with a PE-conjugated HLA-A*02/NS4b214–222 tetramer
(TCmetrix Sàrl.) for 40 min, followed by surface staining for 30 min
using CD8-Alexa700 (clone HIT8a, Biolegend), CD45RA-ECD (clone
2H4LDH11LDB9, Beckman Coulter), CCR7-BrilliantViolet421 (clone
G043H7, Biolegend), CD16-KromeOrange (clone 3G8, Beckman Coul-
ter), CD58-FITC (clone 1C3, BD Biosciences), CD95-PECy7 (clone DX2,
Biolegend) and live/dead cell-marker Vivid-Aqua (Molecular Probes®,
Invitrogen) for 30 min. The ﬂow cytometry gating and sorting strategy
is described in [1]. From each population of CD8 T cells (Table 2) and
each donor (Table 1), 1000 cells were isolated by ﬂow cytometry-
based puriﬁcation using a BD FACSAria I ﬂow cytometer. Puriﬁcations
were performed on two separate days, with samples from donors d1,
d3, d4 and d6 processed in Sort I, and samples from donors d2, d5, d7
and d8 processed in Sort II.
2.4. RNA extraction, ampliﬁcation (SuperAmp miltenyi biotech) and hy-
bridization onto microarray platform for data collection
RNA extraction and ampliﬁcation were performed using the
SuperAmp™ technology from Miltenyi Biotec. Per sample, 100025
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B
raw data from all microarray probes, vertically aligned per sample. B. Signal intensity dis-
alization, ﬁltering, summarization and exclusion of control probes), vertically aligned per
299S.A. Fuertes Marraco et al. / Genomics Data 5 (2015) 297–301cells were puriﬁed directly into 13.5 μl of SuperAmp™ lysis buffer
(Miltenyi Biotec). RNA lysates were incubated for 10 min at 45 °C
and immediately frozen at −20 °C. Thereafter, frozen RNA lysates
were shipped to and processed and analyzed by the Genomic Services
of Miltenyi Biotec. The SuperAmp™ technology performs in-column
immunomagnetic-based mRNA extraction using paramagnetic oligo(dT)
MicroBeads, with bead-bound 1st strand cDNA synthesis and 3′-end tail-
ing for subsequent elution and single-primer global PCR ampliﬁcation and
Klenow labeling. The cDNA sampleswere controlled for integrity by anal-
ysis on Agilent 2100 Bioanalyzer. Samples were hybridized onto AgilentPCA with 
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Fig. 2. Principal component analysis based on all genes: no detectable inﬂuence of observed tech
all samples colored as indicated according to “Day of cell sorting”, “microarray slide”, “microarra
“cell type”.Whole Human GenomeMicroarray 8x60K (V2, one color: Cy3) and ﬂuo-
rescence signals were detected using Agilent's Microarray Scanner Sys-
tem (Agilent Technologies). The image ﬁles were processed with the
Agilent Feature Extraction Software to yield probe intensities. The 40
samples (8 donors × 5 cell populations) were randomly distributed on a
total of 5 microarray slides with 8 spots per slide. In the ﬁles uploaded
into the GEO repository (GSE65804), the name of the raw data ﬁle
contains the 12-digit code of the microarray slide (e.g. 253949422880)
as well as the spot position of the sample within that slide (1.1–1.4 and
2.1–2.4). Supplementary Material 2 provides a sample annotation table,“all genes”
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nical or experimental parameters. Two-dimensional representations of PC1 versus PC2 for
y spot”, “donor” (ordered by increasing years since vaccination), “gender” of the donor and
PCA with “top 10% most variable genes”
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Fig. 3. PCA based on the 10%most variable probes: differentiation gradient in PC1 accord-
ing to cell type. Two-dimensional representation of PC1 versus PC2 for all samples colored
according to “cell type”. Additional colorings, showing no association between the ﬁrst
twoprincipal components and the other observed technical and experimental parameters,
are available in Supplementary Material 1.
Table 3
Probes (and corresponding genes)with largestweight on the secondprincipal component
in PCA based on the 1% probes with highest variance. This component discriminates be-
tween male and female donors, and is dominated by probes measuring the expression
of genes located on the sex chromosomes. Probes with positive weight are highly
expressed in the female donors, and probes with negative weight are highly expressed
in the male donors.
PC2, positive weight PC2, negative weight
A_33_P3405911 (TSIX, chrX) A_23_P364792 (TXLNG2P, chrY)
A_19_P00316565 (TSIX, chrX) A_21_P0006594 (TTTY15, chrY)
A_19_P00327297 (XLOC_008015, chrX) A_23_P324384 (RPS4Y2, chrY)
A_19_P00320438 (TSIX, chrX) A_21_P0006606 (XLOC_008323, chrY)
A_19_P00326132 (TSIX, chrX) A_23_P259314 (RPS4Y1, chrY)
A_19_P00321129 (TSIX, chrX) A_33_P3725324 (USP9Y, chrY)
A_19_P00331623 (XIST, chrX) A_23_P137238 (KDM5D, chrY)
A_19_P00321917 (TSIX, chrX) A_23_P160004 (UTY, chrY)
A_19_P00806762 (TSIX, chrX) A_33_P3261353 (BCORP1, chrY)
A_21_P0006456 (XLOC_008185, chrX) A_21_P0006651 (XLOC_008386, chr10)
300 S.A. Fuertes Marraco et al. / Genomics Data 5 (2015) 297–301relating the raw data ﬁle names to the name and characteristics of the
donor (d1 to d8, Table 1) and the “cell type” (Table 2).
3. Microarray data: quality controls and exploratory analysis
3.1. Data pre-processing
The rawdata from theAgilent Feature Extraction softwarewas proc-
essed and analyzed in R, using mainly functions from the limma pack-
age. The code that was used to generate the ﬁgures in this manuscript,
starting from the raw data deposited in GEO, is available in Supplemen-
tary Material 1. Supplementary Materials 2 and 3 contain the sample
annotation tables that are used in the computational analyses, with
‘sample info’ and ‘targets’ speciﬁed, respectively.PCA with “top 1% mo
cell type: A2_N24b_naivelike
total_cm
total_effector
total_naive
total_Tscm
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Fig. 4. PCA based on the 1%most variable probes: differentiation gradient in PC1 according to ce
for all samples colored according to “cell type” (showing a differentiation gradient in PC1) and
ciation between the ﬁrst two principal components and the other observed technical and expeThe raw data (Fig. 1 A) was background-corrected using the
“normexp” algorithm implemented in limma, and thereafter normalized
between the arrays using quantile normalization. All samples were con-
sidered to be of good quality. In addition to the expression values, the
Agilent Feature Extraction software provides (among other things) ﬂags
indicating whether or not a given feature is detected above the back-
ground level. We used this information to ﬁlter out all probes that were
not detected well above the background (deﬁned as the estimated back-
ground level + 2.6 times the estimated standard deviation of the back-
ground) for any of the samples. This reduced the number of features
from the original 62,976 to 50,477. Finally, we averaged the expression
of replicated probes and ﬁltered out control probes. This further reduced
the number of analyzed features to 41,923.Mapping fromprobe names to
gene identiﬁers was done using the information provided by the Agilent
Feature Extraction software. Fig. 1 B displays the distribution of intensity
values after the pre-processing.
3.2. Exploratory analysis
We used Principal Component Analysis (PCA) to perform explorato-
ry analysis in order to summarize and visualize the data, as well as to
detect potential artifacts and effects of experimental and technical pa-
rameters. The panels of Fig. 2 show the same two-dimensional PCA sam-
ple representation (PC1 versus PC2) based on all 41,923 probes, coloredst variable genes”
−10
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−10 −5 0 5 10
PC1 (14.4%)
PC
2 
(9.
68
%)
gender: female male
ll type and gender differences in PC2. Two-dimensional representations of PC1 versus PC2
to “gender” (showing gender differences in PC2). Additional colorings, showing no asso-
rimental parameters, are available in Supplementary Material 1.
301S.A. Fuertes Marraco et al. / Genomics Data 5 (2015) 297–301according to various sample attributes. No association with any of the
recorded technical parameters can be seen, including: “the day of cell
sorting” (sort I vs. sort II), the position of the samples depending on
the “microarray slide” or “microarray spot”, the “donor” or the “gender”
of the donor. The second principal component shows some discrimina-
tion between the cell populations (“cell type”, top-left panel of Fig. 2).
Since we expected the differences between the different T-cell pop-
ulations to affect a relatively small set of genes, we further performed
exploratory analysis after restricting the data set to the 10% probes
with the highest variance across the 40 samples. Again, no clear impact
of any of the recorded technical parameters was seen (Supplementary
Material 1), but the ﬁrst principal component clearly ordered the ﬁve
cell populations along a gradient of differentiation (Fig. 3)— this obser-
vation is discussed in our recently published study [1]. After reducing
the variable set further to keep only the top 1% probes with highest var-
iance across the samples, the cell population gradient still dominated
the ﬁrst principal component. Considering all the other technical and
experimental parameters enumerated above, the analysis showed that
the second principal component distributed samples according to gen-
der (Fig. 4). The highest weights in the second principal component
were assigned to probes corresponding to genes located on the sex
chromosomes (Table 3), several of which have been previously shown
to be strongly associated with gender [5–7].
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